GHRL and Duchenne muscular dystrophy: Treatment of DMD cells with STO‐609, a CaMKK β inhibitor [51], reduced the levels of pAMPK(T172) and pULK1(S555), and thus preventing the activation of autophagy by obestatin (Figure S1B).